Biotech | October 28, 2021
MSD and MPP sign licensing agreement to make molnupiravir affordable
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
It plans to double its network to 50 centres across India in the next three years
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
_1_256_384.png)
Combination of hardware and data analytics software improves real-time and remote patient monitoring; digitizes and automates time-consuming and critical tasks for medical personnel, reducing administrative tasks by 35 per cent
This funding will help the start-up consolidate its position as a one-stop destination for pet parents as they holistically reimagine the entire pet care ecosystem
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Subscribe To Our Newsletter & Stay Updated
